Treatment of necrolytic migratory erythema in glucagonoma syndrome.
The glucagonoma syndrome is characterized by elevated serum glucagon, a pancreatic alpha-cell tumor, anemia, hypoaminoacidemia, and necrolytic migratory erythema. Necrolytic migratory erythema may cause marked morbidity and is frequently misdiagnosed. A 42-year-old white woman with a 1 1/2-year history of refractory dermatitis (most severe on the lower extremities) had the glucagonoma syndrome. Her severe morbidity was markedly relieved with the administration of intravenous amino acids. This therapy was successful in controlling the necrolytic migratory erythema through recurrences after somatostatin (SMS 201-995), surgical debulking, and chemotherapy proved inadequate.
Shepherd
M E
ME
Department of Dermatology, University of Texas Medical Branch, Galveston 77550.
Raimer
S S
SS
Tyring
S K
SK
Smith
E B
EB
D000328:Adult; D000596:Amino Acids / Q000008:administration & dosage; D004890:Erythema / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D005934:Glucagon / Q000097:blood; D005935:Glucagonoma / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007262:Infusions, Intravenous; D007868:Leg Dermatoses / Q000473:pathology; D009336:Necrosis; D012008:Recurrence; D013577:Syndrome
D000596:Amino Acids; D005934:Glucagon